Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María Pascual-Lucas

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Biomolecular Concepts|December 2, 2014
Epigenetic drugs in Alzheimer's diseaseMar Cuadrado-Tejedor, Julen Oyarzabal, María Pascual Lucas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentMaría Pascual-Lucas, Ana María Lacosta, María Montañés, et al.
Journal of Alzheimer'S Disease : JAD|June 4, 2016
Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer's DiseaseJosé Antonio Allué, Leticia Sarasa, María Izco, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|June 5, 2023
Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 StudyJosé Antonio Allué, María Pascual-Lucas, Leticia Sarasa, et al.
Frontiers in Aging Neuroscience|March 31, 2023
Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivityMin Young Chun, Hyemin Jang, Hee Jin Kim, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersJosé Antonio Allué, Leticia Sarasa, María Pascual-Lucas, et al.
Frontiers in Aging Neuroscience|October 27, 2025
Clinical validation of a plasma-based antibody-free LC-MS method for identifying CSF amyloid positivity in mild cognitive impairmentJosé Antonio Allué, Leticia Sarasa, Noelia Fandos, et al.
Neuropharmacology|July 11, 2012
Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of ADCarolina García-Barroso, Ana Ricobaraza, María Pascual-Lucas, et al.
Alzheimer'S Research & Therapy|January 5, 2023
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive declineMaría Pascual-Lucas, José Antonio Allué, Leticia Sarasa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2025
Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 studyMaría Pascual-Lucas, Ana María Lacosta, María Montañés, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biomolecular Concepts|December 2, 2014
Epigenetic drugs in Alzheimer's diseaseMar Cuadrado-Tejedor, Julen Oyarzabal, María Pascual Lucas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentMaría Pascual-Lucas, Ana María Lacosta, María Montañés, et al.
Journal of Alzheimer'S Disease : JAD|June 4, 2016
Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer's DiseaseJosé Antonio Allué, Leticia Sarasa, María Izco, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|June 5, 2023
Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 StudyJosé Antonio Allué, María Pascual-Lucas, Leticia Sarasa, et al.
Frontiers in Aging Neuroscience|March 31, 2023
Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivityMin Young Chun, Hyemin Jang, Hee Jin Kim, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersJosé Antonio Allué, Leticia Sarasa, María Pascual-Lucas, et al.
Frontiers in Aging Neuroscience|October 27, 2025
Clinical validation of a plasma-based antibody-free LC-MS method for identifying CSF amyloid positivity in mild cognitive impairmentJosé Antonio Allué, Leticia Sarasa, Noelia Fandos, et al.
Neuropharmacology|July 11, 2012
Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of ADCarolina García-Barroso, Ana Ricobaraza, María Pascual-Lucas, et al.
Alzheimer'S Research & Therapy|January 5, 2023
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive declineMaría Pascual-Lucas, José Antonio Allué, Leticia Sarasa, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2025
Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 studyMaría Pascual-Lucas, Ana María Lacosta, María Montañés, et al.
Pageof 2